Samuel J. Reich currently serves as CEO of SAB Biotherapeutics. He was elected CEO of SAB BIO in January 2024. Previously, he served as executive chairman of SAB’s board of directors following SAB’s business combination with Big Cypress Acquisition Corp in October 2021 until January 2026. Prior to joining SAB, he served as Chief Executive Officer, Chief Financial Officer, and a member on the board of directors of Big Cypress Acquisition Corp since its inception in November 2020. Mr. Reich co-founded Biscayne Neurotherapeutics, Inc. in 2011 and served as its Executive Chairman until its sale to Supernus Pharmaceuticals (Nasdaq: SUPN) in October 2018. Biscayne Neurotherapeutics was focused on novel treatments for seizure disorders. Previously, Mr. Reich was the Executive Vice President of OPKO Ophthalmologics, a division of OPKO Health, Inc. (Nasdaq: OPK) from March 2007 to November 2008, where Mr. Reich served on the executive committee and lead the Ophthalmologics business division. Prior to his position at OPKO, Mr. Reich was the Founder and Executive Vice President of Acuity Pharmaceuticals, Inc., where he worked from July 2002 through March 2007, at which time Acuity Pharmaceuticals merged with OPKO Health. Mr. Reich holds a Bachelor of Arts degree with High Honors in Biochemistry from Clark University, cum laude, Phi Beta Kappa, where he received the Margaret Comer award, presented to the top graduating student in the Biological Sciences. He later attended the University of Pennsylvania where he was a Doctoral Candidate in the lab of Jean Bennett. He left prior to defending his thesis to found Acuity Pharmaceuticals, Inc., receiving a Master of Science. He is listed as an inventor on 14 U.S. patents and more than 50 worldwide patents related to the first uses of siRNA as therapeutics.